Canada Life’s Ocular Therapeutix OCUL Stock Holding History

Canada Life’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$102K	Hold	11,976	–	–	﹤0.01%	1689
2025 Q4	$145K	Sell	11,976 -19,938	-62%	-$242K	﹤0.01%	1670
2025 Q3	$400K	Buy	31,914 +4,729	+17%	+$56.5K	﹤0.01%	1634
2025 Q2	$253K	Buy	27,185 +15,209	+127%	+$119K	﹤0.01%	1689
2025 Q1	$88K	Sell	11,976 -18,251	-60%	-$140K	﹤0.01%	1796
2024 Q4	$258K	Buy	30,227 +18,251	+152%	+$178K	﹤0.01%	1729
2024 Q3	$104K	Hold	11,976	–	–	﹤0.01%	1865
2024 Q2	$82K	Buy	+11,976	New	+$73.9K	﹤0.01%	1913
2022 Q2	–	Sell	-4,020	Closed	-$21K	–	2452
2022 Q1	$21K	Hold	4,020	–	–	﹤0.01%	2340
2021 Q4	$28K	Hold	4,020	–	–	﹤0.01%	2310
2021 Q3	$40K	Hold	4,020	–	–	﹤0.01%	2289
2021 Q2	$57K	Hold	4,020	–	–	﹤0.01%	2232
2021 Q1	$65K	Hold	4,020	–	–	﹤0.01%	2213
2020 Q4	$83K	Buy	+4,020	New	+$59.7K	﹤0.01%	2154
2016 Q4	–	Sell	-6,146	Closed	-$42K	–	2539
2016 Q3	$42K	Hold	6,146	–	–	﹤0.01%	2364
2016 Q2	$30K	Sell	6,146 -10,000	-62%	-$99.1K	﹤0.01%	2424
2016 Q1	$155K	Hold	16,146	–	–	﹤0.01%	1471
2015 Q4	$151K	Buy	+16,146	New	+$174K	﹤0.01%	1462

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Canada Life's OCUL Position: Q1 2026 in Review

Canada Life held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 11,976 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1689.

Canada Life first reported a position in OCUL in Q4 2015 and has held it in 18 quarters since. The position peaked at $400K in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Canada Life held 11,976 shares of Ocular Therapeutix worth $102K as of Q1 2026.
Canada Life left its Ocular Therapeutix share count unchanged in Q1 2026.
Ocular Therapeutix made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1689 holding.
Canada Life first reported a position in Ocular Therapeutix in Q4 2015 and has held it in 18 quarters since.
Canada Life's Ocular Therapeutix position peaked at $400K in Q3 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.